CBD Oil For Hives

CBDISTILLERY

Buy CBD Oil Online

Can CBD Oil Be Used To Treat Hives? Today, cannabidiol (CBD) is an increasingly popular ingredient in skincare products, found in everything from beauty creams to salves for inflammatory skin Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Chronic Spontaneous Urticaria (CSU) Patients Each patient will commence the study with

Can CBD Oil Be Used To Treat Hives?

Today, cannabidiol (CBD) is an increasingly popular ingredient in skincare products, found in everything from beauty creams to salves for inflammatory skin conditions. A cursory Google search will reveal CBD-infused products touted as effective treatments for rashes, bug bites, dry skin, acne, and hives. As anyone who has ever dealt with these itchy red welts knows, hives can be a miserable experience, and the quest for relief can be urgent — but research on the efficacy of CBD in treating hives and similar conditions is in its infancy and new knowledge is being gained every day. Keep reading to learn more about CBD and hives from Massachusetts medical marijuana doctor Jordan Tishler.

Benefits of CBD for Skin Inflammation

CBD can benefit a wide variety of medical conditions. The evidence that CBD benefits for hives and other skin conditions hinges on its general anti-inflammatory properties. However, as noted in a thorough overview of CBD’s growing ubiquity in beauty and skincare products by Self magazine, this evidence is largely limited to lab and animal studies.

One especially popular study from the Journal of Dermatological Science in 2007 found that when isolated CBD was applied to human skin cells in the lab, it inhibited the overproduction of skin cells that drives the common skin condition psoriasis. It’s important to make a distinction here between long-term diseases like psoriasis, which may show an inflammatory response due to an underlying problem, versus skin conditions that are acute reactions some outside stimulus — as is often the case with hives, bug bites, and rashes. In other words, evidence that CBD has therapeutic potential for psoriasis is not necessarily evidence for its potential in treating hives.

CBD Oil and Topical Pain Relief

One of the best-established medical uses of marijuana is in the management of pain. However, it is not reasonable to infer that CBD necessarily has these same properties. In one study from the European Journal of Pain using rats showed that topical CBD was able to reduce pain and inflammation from arthritis in the animals. This study, however, used very high doses that would necessitate covering a human from head to toe if the CBD were to be applied topically.

Another wrinkle in the CBD use story is the fact that in all studies, human or mouse, when benefit has been shown, it has always been a very high dose. The dose has consistently been shown to be 10-20mg per kilogram of body weight. Obviously, this is not a problem with tiny mice, but in humans this means 700-1400mg per day, or a whopping $50-100 per day. This is clearly not affordable for most people.

See also  Pineapple Express CBD Oil

Worse, we know that tiny doses, such as you’d get from the products available at the gas station or even at most dispensaries, do nothing. People claiming “miraculous” benefit are simply getting placebo effect.

Circling back to hives, it’s possible that these pain-relieving effects of CBD may help with the discomfort of hives, but it seems unlikely in light of the data we have at present.

Is There Potential for CBD to Treat Hives?

The bottom line is: no notable studies have been performed addressing the effect of CBD, taken orally or topically, on hives. Any products currently claiming to treat hives (and most other skin problems, for that matter) using CBD is really just marketing to people’s hopes. As a recent article in the journal Clinics in Dermatology put it: CBD has become a “trendy” additive to skincare products, but “data are limited regarding its efficacy and safety.”

Contact a Medical Marijuana Healthcare Professional About Treating Your Skin Condition

With so much still unknown about the benefits of CBD, a specialist in medical marijuana and its derivatives is your best source of information on its potential for helping manage hives and other inflammatory skin conditions. Boston medical marijuana doctor Jordan Tishler is a Harvard Medical School cannabis expert and stands ready to help you determine if marijuana may be the right medication for you. To learn more, contact the team at InhaleMD by calling (617) 477-8886 today.

Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Chronic Spontaneous Urticaria (CSU) Patients

Each patient will commence the study with a one month run-in period in which he/she will be administered individual patient Standard of Care :anti-histamines and steroids as needed plus placebo (olive oil).

After the run-in period, doses of CBD will be incresed during the first six weeks of the study.

At the conclusion of the six weeks CBD dose escalation segment of the study, if the 300 mg CBD dose level is deemed safe for two weeks with standard of care doses of anti-histamines, patients will continue receiving 300 mg CBD with Anti-histamines as needed for an additional follow-up period of three month.

Each patient will serve as his/her own control.

Condition or disease Intervention/treatment Phase
Chronic Spontaneous Urticaria Drug: CBD Phase 2

Each patient will commence the study with a one month run-in period in which he/she will be administered individual patient Standard of Care :anti-histamines and steroids as needed plus placebo (olive oil).

At the end of the one month run-in period, all trial subjects will continue on individual Standard of Care plus increasing doses of CBD during the first six weeks of the study. Dosage of CBD will start at 25 mg twice daily and will be increased once every 14 days, if no side effects are observed, to 50 mg twice a day, 100 mg twice a day and finally to 150 mg twice a day CBD respectively. Treatment will be given with food.

See also  Delta 9 CBD Oil

At the conclusion of the six weeks CBD dose escalation segment of the study, if the 300 mg CBD dose level is deemed safe for two weeks with standard of care doses of anti-histamines, patients will continue receiving 300 mg CBD with Anti-histamines as needed for an additional follow-up period of three months. In the case of flare, the patient will be treated with higher dose of Anti-histamines and Steroides if needed in addition to CBD. Once the flare has been brought under control, then another attempt will be made to discontinue the steroids and continue treating with CBD + Anti-histamines only. Each patient will serve as his/her own control.

Laboratory studies will be carried out at the beginning of the study (baseline), and then on a monthly basis until the end of the study.

Adverse events will be continuously assessed throughout the study

Layout table for study information

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: each patient will commence the study with a one month run-in period in which he/she will be administered individual with placebo (olive oil). At the end of the one month run-in period, all trial subjects will receive CBD
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2a Placebo-controlled, Open-label, Single Center Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Chronic Spontaneous Urticaria (CSU) Patients
Actual Study Start Date : February 1, 2020
Estimated Primary Completion Date : December 30, 2020
Estimated Study Completion Date : December 30, 2020

At the end of the one month run-in period, all trial subjects will continue on individual Standard of case plus increasing doses of CBD during the first six weeks of the study. Dosage of CBD will start at 25 mg twice a day and will be increased once every 14 days, if no side effects are observed, to 50 mg twice a day, 100 mg twice a day and finally to 150 mg twice a day CBD respectively. Treatment will be given with food. If the 300 mg CBD dose level is deemed safe for two weeks patients will continue receiving 300 mg CBD +for an additional follow-up period of three months

    Adverse Event reporting of up to 300 mg CBD/day [ Time Frame: 6 month ]

measured by Adverse Events significance of the difference in percent of subjects experienced any Adverse events, drug-related Adverse events and Serious Adverse events between the study groups

Total steroid dose needed to control flares during CBD administration period per patient versus the total steroid dose administered during the one month placebo run-in period

See also  CBD Premium Hair Oil

Total number of days of flares/month experienced per patient during CBD administration versus the total number of days of flares experienced during the one month placebo run-in period

    change in anti histamine use reporting [ Time Frame: 6 month ]

via UAS7, SF36, VAS, Cognitive QoL questionnaire, HDAS at baseline before initiation of CBD administration and at each clinical visit

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
  • Patients with active CSU for at least 4 months which was treated with anti-histamines as well as at least one course of steroids (ex. Prednisone)
  • Age ≥18 years
  • Patients will undergo an ECG and QT parameters will be measured for further analysis.
  • Female subjects who are postmenopausal (absence of menses for ≥ 2 years confirmed by a follicle stimulating hormone test), or who are surgically sterilized may be enrolled. Similarly, women of childbearing potential who had a negative pregnancy test at screening, who are willing to use two medically acceptable methods of contraception for the duration of the study as well as for at least three months after cessation of CBD treatment and who are willing to undergo pregnancy testing according to the study protocol may be enrolled.
  • Female subjects who are not breast-feeding and who have no intention to breast-feed during the term of the trial and for at least three months after cessation of CBD treatment may be enrolled.
  • Subject able to provide written informed consent
  • Viral Hepatitis (HAV, HBV, HCV)
  • HIV
  • Serious psychiatric or psychological disorders
  • Other chronic dermatological conditions under active treatment
  • Active consumption of illicit drugs including cannabis or derivatives for at least three months prior to the study
  • Patients with significant cardiac, respiratory or active malignance disease (except Basel Cell Carcinoma) comorbidities.
  • Any uncontrolled infection at time of registration
  • Renal comorbidity: eGFR < 30 mL/min/1.73m2 (note: CKD Grade 4 is defined as eGFR 15-29 mL/min/1.73 m2)
  • Patient who is taking immunomodulatory medications for other indication
  • Women of child-bearing potential who intend to become pregnant or who are pregnant or breastfeeding

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04439955

How useful was this post?

Click on a star to rate it!

Average rating 4 / 5. Vote count: 1

No votes so far! Be the first to rate this post.